Chembio's DPP(R) HIV-Syphilis Multiplex Test Demonstrates 100% Sensitivity and Specificity in Evaluation by Mexico's Institute

Chembio's DPP(R) HIV-Syphilis Multiplex Test Demonstrates 100% Sensitivity and
Specificity in Evaluation by Mexico's Institute of Epidemiological Diagnosis
and Reference

MEDFORD, N.Y., May 14, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.
(Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious
diseases, announces receipt of an evaluation report from Mexico's Institute of
Epidemiological Diagnosis and Reference (InDRE) regarding the Company's DPP^®
HIV-Syphilis multiplex test, which showed the Company's assay performed with
100% agreement for both markers on all 941 samples tested.

In evaluating the sensitivity and specificity of the Chembio DPP^®
HIV-Syphilis product, 527 biological samples were tested on the HIV line, of
which 158 were true negative and 369 were true positive, and 414 were tested
on the Syphilis line, of which 108 were true negative and 306 were true
positive. The Chembio DPP^® HIV-Syphilis test performed with 100% sensitivity
and 100% specificity on all samples.

The Chembio DPP^® HIV-Syphilis Assay is a single-use immunochromatographic,
rapid screening test for the detection of antibodies both to Human
Immunodeficiency Virus Types 1 and 2 (HIV 1/2) and to Syphilis Treponema
pallidum in fingerstick whole blood, venous whole blood, serum or plasma
samples. The Chembio DPP^® HIV-Syphilis Assay is intended for use as a
point-of-care test to aid in the diagnosis of infection with HIV and/or

Commenting on today's announcement, Javan Esfandiari, Chembio's Senior Vice
President of Research and Development, said, "We are very pleased with the
outstanding results of this evaluation, which is the first of a number of
ongoing external studies, evaluations and registration submissions for this
product. This multiplex test adds the syphilis marker to our recently
FDA-approved DPP^® HIV 1/2 test, and should greatly strengthen the prevention
of mother-to-child transmission (PMTCT) of syphilis. We are seeing strong
interest in this product from global health programs for the PMTCT of HIV,
both because of its potential to reduce the adverse outcomes from untreated
maternal syphilis and the potential to reduce the risk of mother-to-child HIV

Globally, far more pregnant women are estimated to have syphilis than HIV, and
untreated maternal syphilis always results in an adverse pregnancy outcome
such as fetal death, stillbirth, premature birth, low birth weight or
congenital syphilis infection. A dual rapid test for HIV and syphilis could
greatly strengthen PMTCT of syphilis, because programs for the PMTCT of HIV
are much better financed and because they have stronger external and internal
stakeholders. In addition, program costs and supply chains could be more
effectively managed. Also syphilis commonly co-exists in patients with HIV
(prevalence is 14–36%). Genital sores caused by syphilis make it easier to
transmit and acquire HIV infection. The risk of acquiring HIV is estimated to
be two- to-five-times higher if exposed to the virus when syphilis is present.

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets
proprietary rapid diagnostic tests in the growing $10 billion point-of-care
testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests
are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical
Innovations, Inc.). Chembio markets its HIV STAT-PAK^® line of rapid HIV tests
internationally to government and donor-funded programs directly and through
distributors. Chembio has developed a patented point-of-care test platform
technology, the Dual Path Platform (DPP^®) technology, which has significant
advantages over lateral-flow technologies.This technology is providing
Chembio with a significant pipeline of business opportunities for the
development and manufacture of new products based on DPP®. Headquartered in
Medford, NY, with approximately 170 employees, Chembio is licensed by the U.S.
Food and Drug Administration (FDA) as well as the U. S. Department of
Agriculture (USDA), and is certified for the global market under the
International Standards Organization (ISO) directive 13.485.For further
information, visit our website at

Forward-Looking Statements

Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act of 1933,
as amended.Forward-looking statements include statements regarding the
intent, belief or current expectations of the Company and its management.Such
statements are estimates only.Such statements reflect management's current
views, are based on certain assumptions and involve risks and
uncertainties.Actual results, events, or performance may differ materially
from the above forward-looking statements due to a number of important
factors, and will be dependent upon a variety of factors, including, but not
limited to Chembio's ability to obtain additional financing and to obtain
regulatory approvals in a timely manner, as well as the demand for Chembio's
products.Chembio undertakes no obligation to publicly update these
forward-looking statements to reflect events or circumstances that occur after
the date hereof or to reflect any change in Chembio's expectations with regard
to these forward-looking statements or the occurrence of unanticipated
events.Factors that may impact Chembio's success are more fully disclosed in
Chembio's most recent public filings with the U.S. Securities and Exchange

CONTACT: Chembio Diagnostics
         Susan Norcott
         (631) 924-1135, ext. 125
         Anne Marie Fields
         (212) 838-3777
Press spacebar to pause and continue. Press esc to stop.